Palazestrant

Palazestrant can completely inhibit the activity of 17b-estradiol (E2) with IC50 value of 6.4 nM, and inhibit the proliferation of MCF7 and CAMA-1 cells with IC50 value of 1.4-1.6 nM.


Cat. No.: EX-A8461	Purity: >98%

	Chemical structure of Palazestrant

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	685	In-stock
250mg	1185	In-stock
500mg	1985	In-stock
1g	2985	In-stock
2g	get quote	In-stock
5g	get quote	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	OP-1250
CAS No.	2092925-89-6
Purity	>98%
Formula	C28H36FN3O
Mol Weight	449.6033
Color	White to light yellow
State	solid powder
Solubility	DMSO : 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Harmon CL, et al. Methods of treating estrogen receptor-associated diseases such as ER+/HER2+ cancer using an estrogen receptor antagonist: World Intellectual Property Organization, WO2023283329. 2023-01-12. [2]. WHO Drug Information-World Health Organization (WHO). [3]. Parisian AD, et al. Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination. Mol Cancer Ther. 2024 Mar 4;23(3):285-300.
CoA	CoA of Palazestrant

Smiles:	CC(C)(F)CN1[C@H](C2=CC=C(C=C2)OC3CN(C3)CCC)C4=C(C[C@H]1C)C5=CC=CC=C5N4


		Search